GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » Cash Flow from Financing

BioDelivery Sciences International (FRA:BD5) Cash Flow from Financing : €-26.6 Mil (TTM As of Dec. 2021)


View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2021, BioDelivery Sciences International paid €0.0 Mil more to buy back shares than it received from issuing new shares. It received €0.0 Mil from issuing more debt. It paid €0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received €0.0 Mil from paying cash dividends to shareholders. It received €0.0 Mil on other financial activities. In all, BioDelivery Sciences International spent €0.0 Mil on financial activities for the three months ended in Dec. 2021.


BioDelivery Sciences International Cash Flow from Financing Historical Data

The historical data trend for BioDelivery Sciences International's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Cash Flow from Financing Chart

BioDelivery Sciences International Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.23 42.90 35.78 18.68 -27.82

BioDelivery Sciences International Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 -5.00 -4.73 -16.70 -0.13

BioDelivery Sciences International Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

BioDelivery Sciences International's Cash from Financing for the fiscal year that ended in Dec. 2021 is calculated as:

BioDelivery Sciences International's Cash from Financing for the quarter that ended in Dec. 2021 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €-26.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioDelivery Sciences International  (FRA:BD5) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

BioDelivery Sciences International's issuance of stock for the three months ended in Dec. 2021 was €0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

BioDelivery Sciences International's repurchase of stock for the three months ended in Dec. 2021 was €0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

BioDelivery Sciences International's net issuance of debt for the three months ended in Dec. 2021 was €0.0 Mil. BioDelivery Sciences International received €0.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

BioDelivery Sciences International's net issuance of preferred for the three months ended in Dec. 2021 was €0.0 Mil. BioDelivery Sciences International paid €0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

BioDelivery Sciences International's cash flow for dividends for the three months ended in Dec. 2021 was €0.0 Mil. BioDelivery Sciences International received €0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

BioDelivery Sciences International's other financing for the three months ended in Dec. 2021 was €0.0 Mil. BioDelivery Sciences International received €0.0 Mil on other financial activities.


BioDelivery Sciences International Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (FRA:BD5) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

BioDelivery Sciences International (FRA:BD5) Headlines

No Headlines